| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 36.88% | Credit Suisse | $580 → $550 | Maintains | Outperform |
| 06/16/2023 | 36.88% | Wells Fargo | → $550 | Initiates Coverage On | → Overweight |
| 05/08/2023 | 30.66% | Citigroup | $550 → $525 | Maintains | Buy |
| 05/08/2023 | 32.16% | RBC Capital | $582 → $531 | Maintains | Outperform |
| 05/05/2023 | 44.35% | Credit Suisse | $680 → $580 | Maintains | Outperform |
| 02/17/2023 | 44.1% | RBC Capital | $571 → $579 | Maintains | Outperform |
| 02/17/2023 | 69.24% | Credit Suisse | $640 → $680 | Maintains | Outperform |
| 12/07/2022 | 40.62% | RBC Capital | → $565 | Initiates Coverage On | → Outperform |
| 10/28/2022 | 59.28% | Credit Suisse | $715 → $640 | Maintains | Outperform |
| 08/25/2022 | 77.95% | Credit Suisse | → $715 | Initiates Coverage On | → Outperform |
| 07/08/2022 | 74.22% | Citigroup | $750 → $700 | Maintains | Buy |
| 07/30/2021 | 131.46% | Wells Fargo | $735 → $930 | Maintains | Overweight |
| 02/12/2021 | 86.66% | Citigroup | $675 → $750 | Maintains | Buy |
| 02/05/2021 | 80.44% | Jefferies | $660 → $725 | Maintains | Buy |
| 07/31/2020 | 55.55% | Citigroup | $525 → $625 | Maintains | Buy |
| 05/21/2020 | 30.66% | Wells Fargo | $495 → $525 | Maintains | Overweight |
| 05/07/2020 | 30.66% | Citigroup | $480 → $525 | Maintains | Buy |
| 04/20/2020 | 19.46% | Citigroup | $425 → $480 | Maintains | Buy |
| 03/30/2020 | -4.18% | Wells Fargo | $440 → $385 | Maintains | Overweight |
| 03/26/2020 | 7.02% | Barclays | $435 → $430 | Maintains | Overweight |
| 03/20/2020 | 5.77% | Citigroup | $450 → $425 | Maintains | Buy |
| 02/14/2020 | 9.51% | Wells Fargo | $430 → $440 | Maintains | Overweight |
| 01/08/2020 | 7.02% | Wells Fargo | → $430 | Initiates Coverage On | → Overweight |
| 01/07/2020 | 12% | Citigroup | → $450 | Initiates Coverage On | → Buy |
| 08/20/2019 | -0.45% | Goldman Sachs | → $400 | Upgrades | Buy → Conviction Buy |
| 05/09/2019 | -6.67% | Deutsche Bank | $350 → $375 | Maintains | Buy |
| 05/09/2019 | -12.89% | Barclays | $340 → $350 | Maintains | Overweight |
| 03/01/2019 | -12.89% | Deutsche Bank | $330 → $350 | Maintains | Buy |
| 03/01/2019 | -15.38% | Barclays | $315 → $340 | Maintains | Overweight |
| 01/03/2019 | -21.6% | Barclays | → $315 | Upgrades | Equal-Weight → Overweight |
| 11/02/2018 | -21.6% | Barclays | $345 → $315 | Maintains | Equal-Weight |
| 10/17/2018 | -12.89% | Goldman Sachs | → $350 | Initiates Coverage On | → Buy |
| 09/20/2018 | -16.63% | Morgan Stanley | → $335 | Initiates Coverage On | → Equal-Weight |
| 09/05/2018 | -14.14% | Barclays | → $345 | Initiates Coverage On | → Equal-Weight |
| 08/08/2018 | -11.65% | Jefferies | $325 → $355 | Maintains | Buy |
What is the target price for Bio-Rad Laboratories (BIO)?
The latest price target for Bio-Rad Laboratories (NYSE: BIO) was reported by Credit Suisse on August 4, 2023. The analyst firm set a price target for $550.00 expecting BIO to rise to within 12 months (a possible 36.88% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bio-Rad Laboratories (BIO)?
The latest analyst rating for Bio-Rad Laboratories (NYSE: BIO) was provided by Credit Suisse, and Bio-Rad Laboratories maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Bio-Rad Laboratories (BIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Rad Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Rad Laboratories was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
Is the Analyst Rating Bio-Rad Laboratories (BIO) correct?
While ratings are subjective and will change, the latest Bio-Rad Laboratories (BIO) rating was a maintained with a price target of $580.00 to $550.00. The current price Bio-Rad Laboratories (BIO) is trading at is $401.80, which is out of the analyst's predicted range.